Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

PHASE4CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

February 13, 2020

Study Completion Date

August 30, 2020

Conditions
Coronary Artery DiseasePeripheral Arterial DiseaseAtrial Fibrillation
Interventions
DRUG

Rivaroxaban 2.5 mg Tablet

PD assessments will be conducted at 3 time points: i) baseline (while on standard of care antiplatelet therapy), ii) 7-10 days after adjunctive treatment with low dose rivaroxaban, and iii) 7-10 days after dropping aspirin.

Trial Locations (2)

32206

Cardiovascular Research Center,, Jacksonville

32209

UF Health Jacksonville, Jacksonville

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

University of Florida

OTHER

NCT03718429 - Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies | Biotech Hunter | Biotech Hunter